Vera Therapeutics, Inc. (NASDAQ:VERA) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 242,700 shares, an increase of 185.2% from the December 15th total of 85,100 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average trading volume of 58,400 shares, the short-interest ratio is currently 4.2 days.
Shares of VERA stock opened at $19.99 on Friday. The firm’s 50-day simple moving average is $24.93 and its 200-day simple moving average is $20.17. Vera Therapeutics has a 1-year low of $11.30 and a 1-year high of $37.11.
Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Wednesday, November 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.33. Analysts forecast that Vera Therapeutics will post -2.01 earnings per share for the current fiscal year.
Separately, Zacks Investment Research lowered shares of Vera Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 29th.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
Read More: What is quantitative easing?
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.